Neuromuscular Blockade in Critical Care

 

Neuromuscular Blockade in Critical Care: Current Evidence and Clinical Implications

Dr Neeraj Manikath ,claude.ai

Abstract

Neuromuscular blocking agents (NMBAs) have emerged as important therapeutic interventions in the management of critically ill patients. This review examines the pharmacology, indications, benefits, and risks associated with NMBA use in the intensive care unit (ICU), with particular focus on recent evidence regarding their application in acute respiratory distress syndrome (ARDS), targeted temperature management, and status asthmaticus. We discuss monitoring strategies, prevention of associated complications such as critical illness myopathy and polyneuropathy, and provide evidence-based recommendations for clinical practice. Current findings suggest that short-term, early NMBA use in moderate-to-severe ARDS can improve outcomes when appropriately implemented, while prolonged use requires careful consideration of risks and benefits. This review aims to guide clinicians in the judicious use of NMBAs in critical care settings.

Keywords: neuromuscular blocking agents, critical care, intensive care unit, acute respiratory distress syndrome, mechanical ventilation, ICU-acquired weakness

Introduction

Neuromuscular blocking agents (NMBAs) induce paralysis through competitive inhibition of acetylcholine at the neuromuscular junction, preventing depolarization of muscle fibers. While NMBAs have been cornerstones in anesthesia practice since the 1940s, their role in critical care has evolved considerably over the past decades. Initially used primarily to facilitate mechanical ventilation, contemporary applications have expanded to include management of increased intracranial pressure, reduction of oxygen consumption, facilitation of therapeutic hypothermia, and optimization of ventilation in severe acute respiratory distress syndrome (ARDS).

The use of NMBAs in the intensive care unit (ICU) presents unique challenges compared to the operating room, including prolonged administration, altered pharmacokinetics in critically ill patients, monitoring difficulties, and concerns regarding ICU-acquired weakness (ICUAW). Recent landmark trials have significantly influenced our understanding of the benefits and risks associated with NMBA use in critical care, leading to evolving recommendations in clinical practice guidelines.

This review aims to provide a comprehensive analysis of the current evidence regarding NMBA use in critical care, discussing pharmacological considerations, clinical indications, monitoring strategies, complications, and preventive measures to optimize patient outcomes.

Pharmacology of Neuromuscular Blocking Agents in Critical Illness

Classification and Mechanism of Action

NMBAs are classified into depolarizing and non-depolarizing agents based on their mechanism of action at the neuromuscular junction. Succinylcholine, the only depolarizing agent in clinical use, binds to and activates the acetylcholine receptor, causing an initial depolarization followed by flaccid paralysis. Non-depolarizing NMBAs competitively antagonize acetylcholine at the postjunctional nicotinic receptors without causing depolarization.

Non-depolarizing NMBAs are further classified according to their chemical structure into:

1. Benzylisoquinoliniums: Atracurium, cisatracurium, mivacurium
2. Aminosteroids: Pancuronium, vecuronium, rocuronium

Pharmacokinetic Alterations in Critical Illness

Critical illness significantly alters the pharmacokinetics of NMBAs through multiple mechanisms:

1. Volume of distribution changes: Increased capillary permeability, third-spacing, and hypoalbuminemia alter drug distribution.
2. Organ dysfunction: Hepatic and renal impairment affect metabolism and excretion.
3. Acid-base and electrolyte disturbances: Particularly affecting depolarizing agents.
4. Drug interactions: Concomitant medications (aminoglycosides, magnesium, calcium channel blockers) can potentiate neuromuscular blockade.
5. Temperature alterations: Hypothermia prolongs the duration of action of most NMBAs.

These alterations typically result in unpredictable onset, duration, and recovery from neuromuscular blockade in critically ill patients. Table 1 summarizes the key pharmacokinetic properties of commonly used NMBAs in critical care.

Table 1. Pharmacokinetic Properties of Common NMBAs in Critical Care

Agent	Elimination Pathway	Onset (min)	Duration (min)	Special Considerations in Critical Illness
Succinylcholine	Plasma cholinesterase	0.5-1	5-10	Contraindicated in hyperkalemia, burns >24h, crush injuries
Cisatracurium	Hoffman elimination	2-3	30-40	Preferred in hepatic and renal dysfunction
Atracurium	Hoffman elimination and ester hydrolysis	2-3	20-35	Histamine release may be problematic in hemodynamically unstable patients
Vecuronium	Hepatic metabolism, renal excretion	2-3	30-40	Accumulation in renal/hepatic failure
Rocuronium	Primarily hepatic	1-2	30-40	Prolonged in hepatic dysfunction
Pancuronium	Renal excretion (80%)	3-5	60-100	Vagolytic effects; significant accumulation in renal failure

Preferred Agents in Critical Care

The ideal NMBA for critical care should have minimal cardiovascular effects, limited accumulation despite organ dysfunction, and predictable recovery. Cisatracurium has emerged as the preferred agent in many ICU settings due to its organ-independent Hoffman elimination, minimal histamine release, and negligible cardiovascular effects. This pharmacokinetic profile makes it particularly suitable for patients with multiorgan failure.

Clinical Indications for NMBAs in Critical Care

Acute Respiratory Distress Syndrome (ARDS)

Among the various indications for NMBA use in critical care, the management of moderate-to-severe ARDS has the strongest supporting evidence. The theoretical benefits include:

1. Improved patient-ventilator synchrony: NMBAs eliminate patient-initiated breaths that may counteract lung-protective ventilation strategies.
2. Decreased transpulmonary pressure: Reduced risk of barotrauma and volutrauma.
3. Reduced oxygen consumption: Decreased work of breathing and elimination of shivering.
4. Anti-inflammatory effects: Cisatracurium may have direct anti-inflammatory properties independent of its neuromuscular blocking effects.

Several landmark clinical trials have investigated NMBA use in ARDS:

The ACURASYS trial (2010) was a multicenter, randomized controlled trial involving 340 patients with early, severe ARDS (PaO₂/FiO₂ < 150) receiving 48 hours of cisatracurium versus placebo. The NMBA group demonstrated improved adjusted 90-day survival (hazard ratio [HR], 0.68; 95% confidence interval [CI], 0.48-0.98; P=0.04), more ventilator-free days, and reduced barotrauma without increasing muscle weakness.

The more recent ROSE trial (2019) compared early continuous cisatracurium to a light sedation strategy without NMBAs in 1006 patients with moderate-to-severe ARDS. This trial was stopped early for futility, finding no significant difference in 90-day mortality (42.5% vs. 42.8%). However, several factors may explain the contrasting results with ACURASYS, including differences in sedation protocols, timing of NMBA initiation, and higher PEEP utilization in the control group.

A 2022 meta-analysis incorporating both trials found a modest mortality benefit (risk ratio [RR], 0.78; 95% CI, 0.61-0.99) with short-term NMBA use in patients with severe ARDS (PaO₂/FiO₂ < 150). Current practice recommendations suggest considering NMBAs for short-term use (≤48 hours) in patients with PaO₂/FiO₂ < 150 despite optimized ventilatory support and sedation.

Status Asthmaticus

Severe bronchospasm refractory to standard therapies may benefit from NMBAs as rescue therapy. The rationale includes:

• Facilitation of controlled hypoventilation strategies to minimize dynamic hyperinflation
• Reduction in oxygen consumption and carbon dioxide production
• Elimination of ventilator dyssynchrony

Evidence remains limited to observational studies and case series, generally suggesting improved gas exchange and reduced airway pressures with short-term NMBA use. Duration should be minimized given the risk of steroid-NMBA associated myopathy in these patients often receiving high-dose corticosteroids.

Targeted Temperature Management

NMBAs are frequently used during therapeutic hypothermia after cardiac arrest to:

• Prevent shivering, which increases metabolic demand and heat production
• Facilitate tight temperature control

The TTM trial did not specifically address NMBA use, but a substudy noted that 95% of patients received NMBAs during temperature management, with no specific guidance on their optimal use. The duration should be limited to the cooling and rewarming phases when shivering is most prominent.

Elevated Intracranial Pressure (ICP)

NMBAs may be considered for refractory intracranial hypertension to:

• Eliminate posturing or ventilator dyssynchrony that can increase intrathoracic pressure and impede cerebral venous return
• Facilitate medical interventions for elevated ICP

Evidence consists primarily of small observational studies showing temporary ICP reductions. Current brain trauma guidelines suggest considering NMBAs for patients with refractory intracranial hypertension or when seizures are suspected but not apparent due to sedation.

Intra-abdominal Hypertension and Abdominal Compartment Syndrome

NMBAs may temporarily improve abdominal compliance and reduce intra-abdominal pressure. They are considered a second-tier therapy when standard approaches fail, with evidence from case series suggesting temporary improvements. Definitive treatment of the underlying condition remains paramount.

Facilitation of Specific Procedures and Interventions

Short-term NMBA use may be appropriate for:

• Endotracheal intubation
• Prone positioning
• ECMO cannulation
• Complex procedures requiring absolute immobility

Monitoring Neuromuscular Blockade in Critical Care

Appropriate monitoring is essential to ensure adequate blockade while minimizing NMBA exposure. Methods include:

Clinical Assessment

While subjective, clinical assessment involves observation of respiratory efforts, response to stimulation, and ventilator synchrony. The limitations are particularly evident in deeply sedated patients or those with peripheral edema.

Train-of-Four (TOF) Monitoring

Peripheral nerve stimulation (typically ulnar nerve) with evaluation of compound muscle action potentials or observed muscle contractions represents the most practical monitoring approach in the ICU. The interpretation varies by indication:

• For intubation or procedures: Often deep blockade (0/4 twitches) is required
• For ARDS management: Light-to-moderate blockade (1-2/4 twitches) may be sufficient
• To assess recovery: TOF ratio >0.9 indicates adequate neuromuscular recovery

Factors affecting reliability in the ICU include peripheral edema, electrolyte abnormalities, temperature fluctuations, and certain medications.

Quantitative Assessment

Acceleromyography, kinemyography, and electromyography provide more objective measurement of neuromuscular blockade. While common in anesthesia practice, these methods are less frequently utilized in critical care due to practical limitations.

Bispectral Index (BIS) and Electroencephalography (EEG)

These modalities monitor brain activity rather than neuromuscular function. While not directly measuring blockade, they help guide sedation in paralyzed patients where clinical assessment of sedation is impossible.

Complications and Preventive Strategies

ICU-Acquired Weakness (ICUAW)

ICUAW encompasses critical illness polyneuropathy (CIP) and critical illness myopathy (CIM), which can develop independently or concurrently. While early studies implicated NMBAs as independent risk factors, more recent research suggests that the relationship is complex:

1. Duration of exposure: Prolonged NMBA use (>48 hours) increases risk compared to short-term use.
2. Concurrent medications: Combined use with corticosteroids significantly increases risk.
3. Critical illness factors: Severity of illness, hyperglycemia, immobility, and systemic inflammation likely play larger roles than NMBA use alone.

Prevention strategies include:

• Limiting NMBA duration to clinical necessity
• Using proper monitoring to avoid excessive dosing
• Early physical therapy when NMBAs are discontinued
• Strict glycemic control
• Daily sedation interruptions when clinically appropriate

Awareness Under Paralysis

Inadequate sedation during neuromuscular blockade can result in awareness, potentially causing significant psychological trauma. Prevention requires:

• Ensuring adequate sedation before NMBA administration
• Continuous sedation monitoring using sedation scales and/or processed EEG
• Maintaining sedation at deeper levels than typically used for non-paralyzed patients
• Regular assessment for signs of awareness (tachycardia, hypertension, lacrimation)

Pressure Injuries

Immobilized patients are at increased risk for pressure injuries. Preventive measures include:

• Regular repositioning (q2h when hemodynamically stable)
• Specialized pressure-redistributing surfaces
• Meticulous skin care
• Nutritional support

Corneal Abrasions and Ocular Injuries

Paralyzed patients lose the protective blink reflex. Prevention includes:

• Eyelid taping
• Regular application of lubricating eye drops/ointments
• Eye shields in prone positioning

Venous Thromboembolism (VTE)

Immobility increases VTE risk. All paralyzed patients should receive:

• Pharmacological thromboprophylaxis unless contraindicated
• Mechanical thromboprophylaxis when pharmacological methods are contraindicated

Special Considerations

Monitoring Sedation and Pain in Paralyzed Patients

Assessment of sedation and pain becomes challenging when patients cannot communicate or display physical responses. Strategies include:

• Processed EEG monitoring (BIS, PSI, or entropy)
• Assuming pain is present during potentially painful procedures
• Pre-emptive analgesia for nursing care or interventions

NMBA Use During Prone Positioning

Prone positioning in severe ARDS may necessitate temporary NMBA use to:

• Facilitate the turning procedure safely
• Prevent self-extubation or catheter dislodgement

Evidence regarding routine NMBA use throughout prone positioning remains conflicting. A practical approach is to discontinue NMBAs once prone positioning is established if oxygenation and ventilator synchrony permit.

NMBA Use During ECMO

Extracorporeal membrane oxygenation (ECMO) patients may require NMBAs during cannulation and periodically during their course. Pharmacokinetic alterations include:

• Drug sequestration in the ECMO circuit
• Increased volume of distribution
• Variable hepatic and renal function

Monitoring is particularly challenging due to inconsistent drug levels and often requires clinical assessment of ventilator synchrony or more frequent TOF monitoring.

Evidence-Based Recommendations

Based on current evidence, the following recommendations can be proposed:

1. For ARDS: Consider 48-hour cisatracurium infusion in moderate-to-severe ARDS (PaO₂/FiO₂ < 150) refractory to conventional strategies (Grade 2B).
2. For status asthmaticus: Consider short-term NMBA use for refractory bronchospasm causing dangerous dynamic hyperinflation (Grade 2C).
3. For targeted temperature management: Use shortest duration necessary to prevent shivering during cooling and rewarming phases (Grade 2C).
4. For elevated ICP: Consider as rescue therapy for refractory intracranial hypertension (Grade 2C).
5. For monitoring: Use TOF monitoring to titrate to the minimum effective dose (Grade 1B).
6. For prevention of complications:
   • Limit duration when possible (Grade 1B)
   • Ensure adequate sedation (Grade 1A)
   • Implement regular repositioning and pressure injury prevention (Grade 1A)
   • Provide eye care (Grade 1A)
   • Use thromboprophylaxis (Grade 1A)

Conclusion

Neuromuscular blockade represents an important therapeutic strategy in selected critically ill patients. The strongest evidence supports short-term use in moderate-to-severe ARDS, where improved outcomes have been demonstrated when implemented appropriately. The risk-benefit profile becomes less favorable with prolonged use, particularly regarding ICU-acquired weakness.

Optimal use of NMBAs in critical care requires careful patient selection, appropriate monitoring, adequate sedation, and diligent preventive measures against complications. Future research should focus on identifying specific patient populations most likely to benefit from NMBA therapy, optimizing monitoring techniques, and developing strategies to mitigate long-term complications.

References

1. Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010;363(12):1107-1116. doi:10.1056/NEJMoa1005372

2. National Heart, Lung, and Blood Institute PETAL Clinical Trials Network; Moss M, Huang DT, Brower RG, et al. Early neuromuscular blockade in the acute respiratory distress syndrome. N Engl J Med. 2019;380(21):1997-2008. doi:10.1056/NEJMoa1901686

3. Ho ATN, Patolia S, Guervilly C. Neuromuscular blockade in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials. J Intensive Care. 2020;8:12. doi:10.1186/s40560-020-0431-z

4. Bouju P, Tadie JM, Gacouin A, et al. Clinical assessment and train-of-four measurements in critically ill patients treated with recommended doses of cisatracurium or atracurium for neuromuscular blockade: a prospective descriptive study. Ann Intensive Care. 2017;7(1):10. doi:10.1186/s13613-017-0232-2

5. Hraiech S, Forel JM, Papazian L. The role of neuromuscular blockers in ARDS: benefits and risks. Curr Opin Crit Care. 2012;18(5):495-502. doi:10.1097/MCC.0b013e328357efe1

6. Sottile PD, Kiser TH, Burnham EL, et al. An observational study of the efficacy and safety of neuromuscular blockade in acute respiratory distress syndrome. J Crit Care. 2018;43:380-385. doi:10.1016/j.jcrc.2017.12.015

7. Chaudhary S, Sen RK, Jangpangi G, et al. Neuromuscular blocking agents in acute respiratory distress syndrome: A systematic review and meta-analysis of randomized controlled trials. J Clin Anesth. 2022;77:110632. doi:10.1016/j.jclinane.2021.110632

8. Vieillard-Baron A, Matthay M, Teboul JL, et al. Experts' opinion on management of hemodynamics in ARDS patients: focus on the effects of mechanical ventilation. Intensive Care Med. 2016;42(5):739-749. doi:10.1007/s00134-016-4326-3

9. Gainnier M, Roch A, Forel JM, et al. Effect of neuromuscular blocking agents on gas exchange in patients presenting with acute respiratory distress syndrome. Crit Care Med. 2004;32(1):113-119. doi:10.1097/01.CCM.0000104114.72614.BC

10. Guervilly C, Bisbal M, Forel JM, et al. Effects of neuromuscular blockers on transpulmonary pressures in moderate to severe acute respiratory distress syndrome. Intensive Care Med. 2017;43(3):408-418. doi:10.1007/s00134-016-4653-4

11. Griffiths M, Fan E, Baudouin SV. New UK guidelines for the management of adult patients with ARDS. Thorax. 2019;74(10):931-933. doi:10.1136/thoraxjnl-2019-213803

12. Beitler JR, Sarge T, Banner-Goodspeed VM, et al. Effect of titrating positive end-expiratory pressure (PEEP) with an esophageal pressure-guided strategy vs an empirical high PEEP-Fio2 strategy on death and days free from mechanical ventilation among patients with acute respiratory distress syndrome: a randomized clinical trial. JAMA. 2019;321(9):846-857. doi:10.1001/jama.2019.0555

13. Alhazzani W, Belley-Cote E, Møller MH, et al. Neuromuscular blockade in patients with ARDS: a rapid practice guideline. Intensive Care Med. 2020;46(11):1977-1986. doi:10.1007/s00134-020-06227-8

14. Gelinas C, Fillion L, Puntillo KA, Viens C, Fortier M. Validation of the critical-care pain observation tool in adult patients. Am J Crit Care. 2006;15(4):420-427.

15. Chanques G, Conseil M, Roger C, et al. Immediate interruption of sedation compared with usual sedation care in critically ill postoperative patients (SOS-Ventilation): a randomised, parallel-group clinical trial. Lancet Respir Med. 2017;5(10):795-805. doi:10.1016/S2213-2600(17)30304-1

16. Kress JP, Hall JB. ICU-acquired weakness and recovery from critical illness. N Engl J Med. 2014;371(3):287-288. doi:10.1056/NEJMc1406274

17. Patel BK, Pohlman AS, Hall JB, Kress JP. Impact of early mobilization on glycemic control and ICU-acquired weakness in critically ill patients who are mechanically ventilated. Chest. 2014;146(3):583-589. doi:10.1378/chest.13-2046

18. Guérin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368(23):2159-2168. doi:10.1056/NEJMoa1214103

19. Wilcox SR, Brindley PG, Bails D, et al. Pharmacology of neuromuscular blocking agents and reversal agents. Crit Care Clin. 2022;38(1):45-61. doi:10.1016/j.ccc.2021.08.003

20. Greenberg SB, Vender J. The use of neuromuscular blocking agents in the ICU: where are we now? Crit Care Med. 2013;41(5):1332-1344. doi:10.1097/CCM.0b013e31828ce07c

21. Price DR, Mikkelsen ME, Umscheid CA, Armstrong EJ. Neuromuscular blocking agents and neuromuscular dysfunction acquired in critical illness: a systematic review and meta-analysis. Crit Care Med. 2016;44(11):2070-2078. doi:10.1097/CCM.0000000000001839

22. Ballard N, Robley L, Barrett D, Fraser D, Mendoza I. Patients' recollections of therapeutic paralysis in the intensive care unit. Am J Crit Care. 2006;15(1):86-94. doi:10.4037/ajcc2006.15.1.86

23. Murray MJ, DeBlock H, Erstad B, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med. 2016;44(11):2079-2103. doi:10.1097/CCM.0000000000002027

24. Renew JR, Ratzlaff R, Hernandez-Torres V, et al. Neuromuscular blockade management in the critically ill patient. J Intensive Care. 2020;8:37. doi:10.1186/s40560-020-00455-2

25. Warr J, Thiboutot Z, Rose L, Mehta S, Burry LD. Current therapeutic uses, pharmacology, and clinical considerations of neuromuscular blocking agents for critically ill adults. Ann Pharmacother. 2011;45(9):1116-1126. doi:10.1345/aph.1Q004

26. Forel JM, Roch A, Marin V, et al. Neuromuscular blocking agents decrease inflammatory response in patients presenting with acute respiratory distress syndrome. Crit Care Med. 2006;34(11):2749-2757. doi:10.1097/01.CCM.0000239435.87433.0D

27. Bourenne J, Hraiech S, Roch A, et al. Sedation and neuromuscular blocking agents in acute respiratory distress syndrome. Ann Transl Med. 2017;5(14):291. doi:10.21037/atm.2017.07.19

28. Patroniti N, Zangrillo A, Pappalardo F, et al. The Italian ECMO network experience during the 2009 influenza A(H1N1) pandemic: preparation for severe respiratory emergency outbreaks. Intensive Care Med. 2011;37(9):1447-1457. doi:10.1007/s00134-011-2301-6

29. Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46(9):e825-e873. doi:10.1097/CCM.0000000000003299

30. Bellani G, Laffey JG, Pham T, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315(8):788-800. doi:10.1001/jama.2016.0291